title: Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: alloantibody characterization by flow cytometric techniques.
abstract: BACKGROUND
  Patients whose kidney grafts fail develop alloantibodies that react with many HLA molecules. We analyzed the epitope specificity of HLA class I alloantibodies in the sera of 55 patients who had been sensitized by kidney grafts, and investigated the immunogenicity of various polymorphic epitopes.
  
  
  METHODS
  HLA class I alloantibodies were detected and characterized by flow cytometry (FlowPRA beads). Potential "immunizing epitopes" were identified by comparing the amino acid sequences of HLA class I antigens/alleles of the donor, recipient and the antibody-reactivity pattern.
  
  
  RESULTS
  In the 55 anti-HLA class I-positive patients, 82 different antibody reactivity patterns were identified; all but 5 (94%) were determined by a "public epitope" of donor HLA-A and/or -B molecules. Forty-five of 50 patients who showed HLA-A Res-MMs with their donors produced HLA-A antibodies, but only 31 of 51 subjects with HLA-B Res-MMs produced HLA-B antibodies (P=0.001; O.R.=5.81). The antibody patterns were specific for a "single" epitope of the mismatched donor molecules in 91% of patients. Forty-three of the 120 (36%) mismatched HLA-A and/or -B epitopes were positively correlated with antibody production. The polymorphic determinants of higher immunogenic capacity were b80N (Bw6-associated) and ab82-83LR (Bw4-associated) public epitopes.
  
  
  CONCLUSIONS
  The humoral immune response against a kidney graft mainly produces HLA class I antibodies specific for "public epitopes" of mismatched donor molecules. A "single" donor-epitope may determine the production of a spread antibody pattern. In renal transplantation, epitope matching is better than HLA antigen matching for avoiding or minimizing development of HLA antibodies.
authors.affiliation: National Council of Research, Institute of Organ Transplantation and Immunocytology, Rome, Italy. antonina.piazza@itoi.cnr.it
authors.forename: Antonina
authors.initials: A
authors.lastname: Piazza
authors.forename: Elvira
authors.initials: E
authors.lastname: Poggi
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Ozzella
authors.forename: Laura
authors.initials: L
authors.lastname: Borrelli
authors.forename: Palmina I
authors.initials: PI
authors.lastname: Monaco
authors.forename: Alessandra
authors.initials: A
authors.lastname: Scornajenghi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tisone
authors.forename: Domenico
authors.initials: D
authors.lastname: Adorno
mesh_terms: D000918:Antibody Specificity; D000937:Antigen-Antibody Reactions; D000939:Epitopes / Q000032:analysis*; D005434:Flow Cytometry; D015234:HLA-A Antigens / Q000276:immunology; D015235:HLA-B Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007518:Isoantibodies / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology*; D012086:Reoperation; D017211:Treatment Failure
chemical_list: D000939:Epitopes; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D007518:Isoantibodies